ArticleCell death discovery2025
Prpf4 sequentially regulates the expansion and maturation of erythrocyte through distinct mechanisms.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The proliferation of early erythrocyte and the subsequent maturation are critical events during erythropoiesis, while how these two independent but interconnected processes are efficiently orchestrated during erythropoiesis is largely unknown. Prpf4 expression is enriched from Pre-Colony Forming Unit-Erythroid (PreCFU-E) to Nucleated Erythrocytes, especially in the CFU-E cells, implying that Prpf4 plays a critical role in erythropoiesis. Here, we demonstrate that prpf4 sequentially regulates erythrocyte proliferation and maturation during zebrafish definitive hematopoiesis. The data show that prpf4 mutation results in severe defects in erythropoiesis, characterized by a substantial reduction in erythroid cell numbers and impaired erythrocyte maturation. Further analysis indicates that prpf4 mutation leads to cell cycle arrest of erythrocytes at the S and G2/M phases, as well as a significant increase in erythrocyte apoptosis. Mechanistically, prpf4 mutation leads to DNA damage and the subsequent activation of the DNA damage response, triggering the ATM/CHK2-p53 signaling pathway. This process inhibits the proliferation of early erythrocyte and induces erythrocyte apoptosis. On the other hand, the data reveal that prpf4 mutation causes significant defects in skipped-exon during pre-mRNA splicing, accompanied by severe splicing defect in slc25a39 pre-mRNA. This results in a significant downregulation of slc25a39 mRNA, which partially impairs erythrocyte maturation during late erythropoiesis. In conclusion, we identify that prpf4 sequentially regulates early erythrocyte proliferation and subsequent erythrocyte maturation. This dual function of prpf4 partially explains how early erythrocyte proliferation and late maturation are efficiently coordinated during erythropoiesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.